These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10987101)

  • 21. [Combined use of quinolones with other antibiotics in treatment of experimental plague infection].
    Shcherbaniuk AI; Kasatkina IV; Ryzhko IV
    Antibiot Khimioter; 1994 May; 39(5):38-40. PubMed ID: 7857159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of immunization protection efficacy of plague subunit vaccine].
    Zhang QW; Qi ZZ; Xin YQ; Yang YH; Wu HL; Yang HQ; Feng JP; Jin X; Cui BZ; Wang T; Wu BC; Qiu YF; Wang W; Guo ZB; Wang ZY; Yang RF; Wang H; Wang XY
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Sep; 43(9):785-8. PubMed ID: 20137561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electroporation of a multivalent DNA vaccine cocktail elicits a protective immune response against anthrax and plague.
    Albrecht MT; Livingston BD; Pesce JT; Bell MG; Hannaman D; Keane-Myers AM
    Vaccine; 2012 Jul; 30(32):4872-83. PubMed ID: 22633906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model.
    Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM
    FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinetics of memory B cell and plasma cell responses in the mice immunized with plague vaccines.
    Zhang X; Wang Q; Bi Y; Kou Z; Zhou J; Cui Y; Yan Y; Zhou L; Tan Y; Yang H; Du Z; Han Y; Song Y; Zhang P; Zhou D; Yang R; Wang X
    Scand J Immunol; 2014 Mar; 79(3):157-62. PubMed ID: 24383627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G; Khan AA; Rao DN
    Scand J Immunol; 2010 Mar; 71(3):186-98. PubMed ID: 20415784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs.
    Feodorova VA; Pan'kina LN; Savostina EP; Sayapina LV; Motin VL; Dentovskaya SV; Shaikhutdinova RZ; Ivanov SA; Lindner B; Kondakova AN; Bystrova OV; Kocharova NA; Senchenkova SN; Holst O; Pier GB; Knirel YA; Anisimov AP
    Vaccine; 2007 Nov; 25(44):7620-8. PubMed ID: 17913308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice.
    Uppada SB; Bhat AA; Sah A; Donthamshetty RN
    Vaccine; 2011 Nov; 29(50):9352-60. PubMed ID: 22001881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270.
    Qi Z; Zhou L; Zhang Q; Ren L; Dai R; Wu B; Wang T; Zhu Z; Yang Y; Cui B; Wang Z; Wang H; Qiu Y; Guo Z; Yang R; Wang X
    Vaccine; 2010 Feb; 28(6):1655-60. PubMed ID: 20079562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The plague: disease and vaccine?].
    Michel P; Rasoamanana B; Rasolofonirina N; Roux J
    Dakar Med; 1992; 37(2):183-9. PubMed ID: 1345094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Virulence of rifampicin and quinolone resistant mutants of strains of plague microbe with Fra+ and Fra- phenotypes].
    Ryzhko IV; Shcherbaniuk AI; Samokhodkina ED; Tsuraeva RI; Mishn'kin BN; Kasatkina IV; Zhigalova TA
    Antibiot Khimioter; 1994 Apr; 39(4):32-6. PubMed ID: 7826172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates.
    Williamson ED; Flick-Smith HC; Waters E; Miller J; Hodgson I; Le Butt CS; Hill J
    Microb Pathog; 2007 Jan; 42(1):11-21. PubMed ID: 17107769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.
    Jones T; Adamovicz JJ; Cyr SL; Bolt CR; Bellerose N; Pitt LM; Lowell GH; Burt DS
    Vaccine; 2006 Mar; 24(10):1625-32. PubMed ID: 16243411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V).
    Fellows P; Adamovicz J; Hartings J; Sherwood R; Mega W; Brasel T; Barr E; Holland L; Lin W; Rom A; Blackwelder W; Price J; Morris S; Snow D; Hart MK
    Vaccine; 2010 Nov; 28(49):7748-56. PubMed ID: 20920572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Duration and intensity of postvaccinal immunity to plague in experimental animals].
    Chicherin IuV; Evstigneev VI; Lebedinskiĭ VA
    Zh Mikrobiol Epidemiol Immunobiol; 1977 May; (5):95-8. PubMed ID: 409008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant (F1+V) vaccine protects cynomolgus macaques against pneumonic plague.
    Williamson ED; Packer PJ; Waters EL; Simpson AJ; Dyer D; Hartings J; Twenhafel N; Pitt ML
    Vaccine; 2011 Jun; 29(29-30):4771-7. PubMed ID: 21570437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of the latest fluoroquinolones against experimental Yersinia pestis.
    Steward J; Lever MS; Russell P; Beedham RJ; Stagg AJ; Taylor RR; Brooks TJ
    Int J Antimicrob Agents; 2004 Dec; 24(6):609-12. PubMed ID: 15555886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Construction of variants of Yersinia pestis EV76 (RIEG line) vaccine strain differing in antibiotic resistance spectra with stage-by-stage transduction of R-transposons].
    Cherniavskaia AS; Morozova IV; Lebedeva SA; Zarenkov MI
    Antibiot Khimioter; 2005; 50(7):13-7. PubMed ID: 16768208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A molecular basis of the plague vaccine development].
    Dentovskaia SV; Kopylov PKh; Ivanov SA; Ageev SA; Anisimov AP
    Mol Gen Mikrobiol Virusol; 2013; (3):3-12. PubMed ID: 24364139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.